Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations

• Project/Area Number: 26430163
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Okayama University
• Principal Investigator: Hotta Katsuyuki 岡山大学, 大学病院, 教授 (70379816)
• Co-Investigator(Kenkyū-buntansha): 木浦 勝行 岡山大学, 大学病院, 教授 (10243502)
• Research Collaborator: Kato Yuka 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Tamura Tomoki 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Ninomiya Kiichiro 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Ohashi Kadoaki 岡山大学病院, 呼吸器・アレルギー内科
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
• Keywords: 肺癌 / EGFR / IL-6 / チロシンキナーゼ阻害薬 / EGFR遺伝子変異陽性非小細胞肺がん / EGFR-TKI / インターロイキン6（IL-6）

Outline of Final Research Achievements

In our study, in 52 patients with EGFR-mutat lung cancer who received gefitinib, EGFR tyrosine kinase inhibitor (TKI), the high IL-6 expression group, accouting for 46%, tended to have poor progression-free survival as compared with the low expression group. In pre-clinical studies using cell lines, the efficacy of EGFR tyrosine kinase inhibitor was related to IL-6 expression level. Thus, EGFR-TKI treatment alone seems insufficient in the high IL-6 expression group, and further treatment strategy should be developed.

Research Products

• [Journal Article] Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. (2018)
  • Author(s): Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K.
  • Journal Title: Biochem Biophys Res Commun. Volume: 495 Issue: 1 Pages: 360-367
  • DOI: 10.1016/j.bbrc.2017.10.175
  • Peer Reviewed
• [Presentation] Interleukin-6 Is a Valuable Predictive Marker for Therapeutic Effect of Gefitinib in Patients with Advanced NSCLC Harboring EGFR Mutations (2015)
  • Author(s): Y. Kato, K. Hotta, T. Tamura, T. Tanaka, K. Ichimura, K. Ohashi, T. Kubo, E. Ichihara, M. Tanimoto, K. Kiura
  • Organizer: 第16回世界肺癌会議
  • Place of Presentation: 米国コロラド州デンバー
  • Year and Date: 2015-09-06
  • Int'l Joint Research